JANNEY DANIEL — SEC insider filings

SEC reporting owner CIK 1198325. 24 insider filings on record with FilingPulse; latest filed 2026-09-16.

Transaction summary — filings shown

Covers all 24 filings on record, filed 2020-08-07 to 2026-09-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Krystal Biotech, Inc. (KRYS)Director14—35 legs · 296,964 sh · $39,886,54110
Allakos Inc. (ALLK)Director81 leg · 475,000 sh · $2,384,5008 legs · 47,341 sh · $5,669,1363
Tyra Biosciences, Inc. (TYRA)10% owner11 leg · 156,250 sh · $2,500,000—3
Esperion Therapeutics, Inc. (ESPR)Director1——1

Insider filings — JANNEY DANIEL

FiledFormIssuerReported transactionsSource
2026-09-164Krystal Biotech, Inc. (KRYS)Grant/award (A): 1,187 (derivative) @ $0 · Grant/award (A): 471 (derivative) @ $0EDGAR
2026-03-034Krystal Biotech, Inc. (KRYS)Sale (S): 9,430 @ $275.45 · Sale (S): 2,373 @ $276.17EDGAR
2026-02-264Krystal Biotech, Inc. (KRYS)Option exercise (M): 37,895 @ $2.46 · Sale (S): 569 @ $262.91 · Sale (S): 1,733 @ $264.12 · Sale (S): 3,557 @ $265.08 · Sale (S): 8,986 @ $266.18 · Sale (S): 11,673 @ $266.97 · +16 moreEDGAR
2025-06-304Krystal Biotech, Inc. (KRYS)Grant/award (A): 5,000 (derivative) @ $0EDGAR
2024-07-014Krystal Biotech, Inc. (KRYS)Grant/award (A): 5,000 (derivative) @ $0EDGAR
2023-07-034Krystal Biotech, Inc. (KRYS)Grant/award (A): 6,800 (derivative) @ $0EDGAR
2023-06-094Krystal Biotech, Inc. (KRYS)Sale (S): 4,604 @ $127.96 · Sale (S): 1,073 @ $129.02 · Sale (S): 5,388 @ $128.73 · Sale (S): 5,000 @ $127.96 · Sale (S): 10,000 @ $127.96 · Sale (S): 5,000 @ $127.86 · +3 moreEDGAR
2023-05-304Allakos Inc. (ALLK)Grant/award (A): 86,762 (derivative) @ $0EDGAR
2023-05-234Krystal Biotech, Inc. (KRYS)Sale (S): 50,000 @ $95.02EDGAR
2023-05-114Krystal Biotech, Inc. (KRYS)Sale (S): 17,100 @ $90.74EDGAR
2023-04-214Krystal Biotech, Inc. (KRYS)Sale (S): 7,900 @ $90.32EDGAR
2022-09-234Allakos Inc. (ALLK)Purchase (P): 475,000 @ $5.02EDGAR
2022-07-014Krystal Biotech, Inc. (KRYS)Grant/award (A): 6,800 (derivative) @ $0EDGAR
2022-05-274Allakos Inc. (ALLK)Grant/award (A): 99,590 (derivative) @ $0EDGAR
2021-12-144Krystal Biotech, Inc. (KRYS)Sale (S): 100,000 @ $70.50EDGAR
2021-10-144Allakos Inc. (ALLK)Grant/award (A): 7,700 (derivative) @ $0EDGAR
2021-09-174Tyra Biosciences, Inc. (TYRA)
jointly with Alta Partners NextGen Fund II Management, LLC, Alta Partners NextGen Fund II, L.P., Hudson Peter A
Conversion (C): 3,811,117 · Purchase (P): 156,250 @ $16 · Conversion (C): 1,212,122 (derivative) @ $0 · Conversion (C): 255,160 (derivative) @ $0EDGAR
2021-07-024Krystal Biotech, Inc. (KRYS)Grant/award (A): 6,800 (derivative) @ $0EDGAR
2021-05-284Esperion Therapeutics, Inc. (ESPR)Grant/award (A): 12,376 @ $0EDGAR
2021-03-304Allakos Inc. (ALLK)Sale (S): 14,808 @ $115.01 · Sale (S): 2,500 @ $116.09EDGAR
2021-03-244Allakos Inc. (ALLK)Sale (S): 9,030 @ $119.46 · Sale (S): 4,118 @ $120.22EDGAR
2021-03-164Allakos Inc. (ALLK)Sale (S): 4,071 @ $124.18 · Sale (S): 6,708 @ $124.56EDGAR
2021-03-114Allakos Inc. (ALLK)Sale (S): 100 @ $125 · Sale (S): 6,006 @ $124.62EDGAR
2020-08-074Krystal Biotech, Inc. (KRYS)Grant/award (A): 6,800 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-08-06 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1198325 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs